fda approv rinvoq humira play crucial role
maintain rate buy also maintain
tp tp base
forward price-to-earnings multipl adjust ep
provid upsid potenti
upsid potenti increas due fall
stock price jun base
previou report stock price fell
result later show upward trend sinc mid-
august got key fda approv rinvoq
upadacitinib treat rheumatoid arthriti latest fda
approv biggest regulatori victori far year
might import immunolog win
compani sinc humira drug appear even better
predecessor
mani investor still cautiou regard compani
effort overcom headwind humira maintain
recommend expect revenu
expect top-lin revenu grow
estim base follow factor increas
revenu hematolog oncolog product fda
approv skyrizi venclexta acquisit
allergan mavupharma
total revenu decreas basi
increas oper
ep adjust ep
compani nameabbvi inctickerabbvstock ratingbuyunchangedindustri viewoverweightpositivepric oct week week volum volum mrq forward ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth abbvi inc octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
total revenu imbruvica increas
increas
increas due continu penetr
imbruvica patient cll well favor
total revenu venclexta increas
increas
increas due market share gain
follow addit regulatori approv venclexta
treatment patient relapsed/refractori cll
aml
allergan plc announc compani
enter definit transact agreement
acquir allergan cash stock transact
transact equiti valu billion
announc acquisit mavupharma
privat held biopharmaceut compani focus novel
approach target sting stimul interferon
gene pathway treatment cancer
announc food drug administr
fda european commiss ec approv skyrizi
risankizumab treatment moder sever
plaqu psoriasi adult patient candid
current price-to-earnings lower
price-to-earnings surg
januari price-to-earnings fallen sinc due fall
stock price result failur drug rova
acquir averag price-to-earnings
expect forward price-to-earnings
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date oct last split factor new per old n/a last split date n/atrad inform inc octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research sale gener oper total oper oper interest incom incom provis incom net prefer net incom avail common weight averag share estim annual actual annual actual quarterli abbvi inc octob
balanc sheet short term total st receivablesaccount -- total current prepaid defer tax asset current -- -- -- -- -restrict -- -- current total current long-term assetsgross properti plant accumul net properti plant long-term defer tax asset -- -- long-term total current liabilitiesaccount accru -- short-term current portion lt current total current long-term liabilitieslong-term pension post-retir -- def tax liabil non-curr total common equitycommon addit paid retain treasuri comprehens incom total common stockhold equitytot liabil equitytot liabil actual annual actual quarterli abbvi inc octob
oper cash flow decreas compar
due improv result oper result increas oper earn lower defin
benefit plan contribut off-set higher payment incom tax interest abbvi
contribut defin benefit plan
net cash use invest activ compar net cash provid
invest activ includ net sale matur invest secur
total payment made acquisit invest capit expenditur
net cash use financ activ decreas compar
includ repay term loan credit agreement
schedul matur june
net incom oper activ depreci amort amort goodwil intang depreci amort total asset write-down restruc cost stock-bas compens oper activ chang account receiv chang inventori chang account payabl chang net oper asset oper invest activ capit expenditur acquisit invest market equiti securt invest activ invest financ activ short term debt issu long-term debt issu total debt issu short term debt repaid long-term debt repaid total debt repaid issuanc common stock repurchas common stock common prefer stock dividend paid financ activ financ chang equival foreign exchang rate adjust net chang annual actual quarterli abbvi inc octob
inc second quarter revenu increas market
decreas market adjust ep growth
compar
total revenu decreas report basi increas
cc basi compar total
revenu increas compar
total intern revenu decreas
report basi decreas cc basi
compar
increas
compar
cog decreas compar
adjust cog decreas
compar gross profit increas
compar gross margin increas
compar
sg expens decreas compar
adjust sg expens decreas
compar sg expens revenu
decreas compar
 expens decreas compar
adjust expens decreas
compar expens revenu
rel flat compar acquir in-process
oper incom increas compar
net interest expens increas
compar net expens increas
compar
effect tax rate increas compar
adjust effect tax rate decreas compar
gaap ep
adjust ep
net incom decreas compar
adjust net incom increas
compar ep
compar adjust ep
compar
compar
total revenu decreas report basi increas
cc basi compar total
revenu increas compar
total intern revenu decreas
actual currenc rate decreas constant currenc rate
compar
cog decreas compar
adjust cog decreas compar
gross profit increas compar
gross margin increas compar
increas favor impact primarili expir
humira royalti partial off-set higher intang asset amort
imbruvica profit share arrang
sg expens decreas compar
adjust sg expens decreas
compar sg expens
revenu decreas compar
compar
decreas sg expens revenu favor impact
lower charit contribut prior year contribut
certain not-for-profit organ recur intern
humira expens reduct partial off-set new product launch expens
transact cost associ propos allergan
acquisit addit sg expens revenu unfavor
impact restructur charg off-set decreas litig
 expens decreas compar
adjust expens decreas
compar expens revenu
rel flat compar acquir in-process
 compar
oper incom increas compar
net interest expens increas
compar increas net interest
expens due unfavor impact higher interest rate
compani debt oblig higher averag outstand debt balanc
increas
compar
net expens increas compar
net expens includ charg relat
chang fair valu conting consider liabil
compar charg
fair valu conting consider liabil impact passag
time multipl input includ probabl success
achiev regulatory/commerci mileston discount rate estim
amount futur sale acquir product market-bas
increas
compar
chang fair valu repres higher
probabl success higher estim futur sale declin interest
rate higher probabl success result april
regulatori approv skyrizi treatment moder sever plaqu
chang fair valu repres higher estim
futur sale passag time partial off-set effect rise
effect tax rate increas compar
adjust effect tax rate remain flat
compar
increas effect tax rate due benefici impact time
provis tax cut job act relat earn certain
foreign subsidiari prior year chang jurisdict mix
earn includ chang fair valu conting consider liabil
increas partial off-set favor resolut variou tax
posit current year
gaap ep
compar
net incom decreas compar
adjust net incom increas
compar
gaap ep compar adjust
ep compar
total revenu
humira decreas
decreas
total revenu
 increas
increas
abbvi product focus treat condit chronic
autoimmun diseas rheumatolog gastroenterolog dermatolog
oncolog includ blood cancer virolog includ hepat hcv
human immunodefici viru hiv neurolog disord
parkinson diseas metabol diseas includ thyroid diseas
complic associ cystic fibrosi pain associ
endometriosi well seriou health condit
total revenu humira decreas report basi
cc basi compar
decreas report basi cc basi
compar
decreas humira revenu result direct biosimilar
competit certain intern market partial off-set market
total revenu increas
compar increas
compar due market growth across
indic
total intern revenu decreas report basi
cc basi compar
decreas report basi cc basi
compar decreas
due direct biosimilar competit certain intern
market follow expir european union composit
matter patent adalimumab octob
biosimilar competit humira expect unit state
continu pursu strategi intend
differenti humira compet product add
sustain humira
total revenu
imbruvica increas
increas
total revenu skyrizi
follow april regulatori approv treatment
moder sever plaqu psoriasi
total revenu total
revenu
imbruvica venclexta
total revenu imbruvica increas
compar increas
compar increas due
continu penetr imbruvica patient cll well
total revenu
venclexta decreas
increas
total revenu increas
compar increas
compar total collabor
revenu increas compar
increas
compar
total revenu venclexta increas
compar increas
compar increas
due market share gain follow addit regulatori approv
venclexta treatment patient relapsed/refractori cll
aml
imbruvica venclexta
total revenu
mavyret decreas
decreas
total revenu increas compar
compar
total intern revenu increas
compar
compar
total revenu
viekira decreas
decreas
total revenu mavyret decreas report basi
cc basi compar
decreas report basi cc
basi compar
decreas primarili driven lower patient volum certain
total revenu decreas
compar increas
compar total intern
revenu decreas cc basi
compar decreas cc basi
compar
total revenu viekira decreas report basi
cc basi compar
decreas report basi cc
basi compar
total revenu
lupron decreas
increas
total revenu creon increas
compar increas
compar total revenu increas
due continu market growth favor price creon maintain
market leadership pancreat enzym market
total revenu
synthroid increas
increas
total revenu lupron decreas report basi
cc basi compar
decreas report basi increas cc
basi compar
total revenu decreas
compar increas
compar total intern revenu
decreas report basi increas cc basi
compar decreas
report basi increas cc basi
compar
total revenu synthroid increas
compar increas
compar
total revenu synagi decreas report basi
cc basi compar
decreas report basi cc basi
compar
total revenu
duodopa increas
increas
cc basi
total revenu
decreas
cc basi
total revenu duodopa increas report basi
cc basi compar
increas report basi cc basi
compar due increas
total revenu increas
compar increas
compar total intern revenu
increas report basi compar
increas report basi
compar
total revenu sevofluran decreas report basi
cc basi compar
decreas report basi cc basi
compar
total revenu decreas
compar decreas
compar
total intern revenu decreas report basi
cc basi compar
decreas report basi cc basi
compar
total revenu
kaletra decreas
decreas
total revenu kaletra decreas report basi
cc basi compar
decreas report basi cc basi
compar
total revenu decreas
compar decreas
compar
total intern revenu increas report basi
cc basi compar
decreas report basi increas
cc basi compar
total revenu androgel decreas
compar decreas
compar
allergan plc announc compani enter
definit transact agreement acquir allergan
cash stock transact transact equiti valu billion
world congress
patient moder
sever psoriasi
propos acquisit allergan transform compani
provid immedi scale divers profit growth
platform enhanc long-term invest sustain focu
innov scienc increas global commerci scale maxim
valu allergan portfolio combin compani produc robust
cash flow support continu dividend growth reduct debt level
announc food drug administr fda european
commiss ec approv skyrizi risankizumab treatment
moder sever plaqu psoriasi adult patient candid
approv skyrizi base result four pivot phase
studi immvent immhanc evalu
patient moder sever plaqu psoriasi skyrizi part
collabor boehring ingelheim bi
lead develop commerci global
world congress dermatolog present new two-year data
show skyrizi patient moder sever psoriasi maintain
long-term result phase immhanc studi show percent
percent patient treat continu skyrizi experienc complet
skin clearanc defin static physician global assess spga
psoriasi area sever respect week among
patient achiev spga week new safeti find
observ two year
european congress rheumatolog present new long-term
data upadacitinib phase studi select-earli select-compar
show significantli higher proport patient rheumatoid arthriti
treat upadacitinib monotherapi combin methotrex
maintain clinic remiss compar adalimumab plu
respect week
addit find integr safeti analysi across five studi
select phase clinic program support well-character safeti
profil upadacitinib patient moder sever activ
announc fda approv venclexta venetoclax combin
obinutuzumab chemotherapy-fre combin regimen
previous untreat chronic lymphocyt leukemia cll small lymphocyt
fda review submiss venclexta real-tim
oncolog review pilot program approv base data
phase trial evalu venclexta combin obinutuzumab
compar patient receiv chlorambucil plu obinutuzumab
fourth approv fifth breakthrough therapi design
venclexta venetoclax develop roch jointli
commerci genentech member roch group
 outsid
american societi clinic oncolog annual meet
forti abstract includ result phase trial
venclexta plu obinutuzumab previous untreat cll patient result
phase bellini trial venclexta plu bortezomib
dexamethason patient relapsed/refractori r/r multipl myeloma
mm result phase trial imbruvica ibrutinib
asymptomat watch wait popul cll
also present new imbruvica six-year five-year data
phase reson trial respect evalu long-
term safeti efficaci benefit cll/sll patient imbruvica jointli
develop commerci janssen biotech inc
approv venclexta
combin
obinutuzumab
combin regimen
leukemia lymphocyt
announc
fda lift partial
clinic hold place
investig
treatment r/r mm
announc fda lift partial clinic hold place canova
phase trial evalu venclexta investig treatment r/r
mm canova trial evalu venclexta combin
dexamethason versu pomalidomid combin dexamethason
patient r/r mm posit transloc abnorm
partial clinic hold remov canova base upon agreement
revis canova studi protocol includ new risk mitig
measur protocol-specifi guidelin updat futil criteria
genet biomark among common routin test
genet abnorm patient mm
provid updat depatuxizumab mafodotin depatux-m
glioblastoma program announc phase studi
meet primari endpoint overal surviv interim analysi
demonstr surviv benefit newli diagnos patient receiv
independ data monitor committe respons interim analysi
data review phase recommend stop studi due
lack surviv benefit patient receiv depatux-m enrol
on-going depatux-m studi halt result submit
present medic confer public peer-review
american academi neurolog annual meet present six
difficult treat neurolog condit investig present
pharmacokinet safety/toler data
infus investig treatment advanc parkinson
diseas investig also present data phase multiple-dos studi
elezanumab patient relaps form multipl sclerosi
announc resolv humira adalimumab litig
bi term resolut grant bi non-exclus
licens humira-rel intellectu properti unit state
 licens bi begin juli bi pay royalti
licens humira patent acknowledg valid enforc
licens patent make payment form bi
announc acquisit mavupharma privat held
biopharmaceut compani focus novel approach target sting
stimul interferon gene pathway treatment cancer sting
pathway signal play import role gener immun
respons direct tumor enhanc sting signal shown
promis varieti tumor model
sting pathway stimul potenti increas suscept
tumor broaden treatment option patient collabor
broaden oncolog research platform expand develop
potenti life-chang treatment patient
announc
acquisit
compani focus
novel approach
target sting
pathway
treatment cancer
rais
rang
gaap ep increas
increas
updat previous announc ep guidanc rang
repres growth midpoint
includ non-cash charg skyrizi conting consider follow
regulatori approv
rais previous announc adjust ep guidanc rang
repres growth mid-point
abbvi adjust dilut ep guidanc exclud per share
intang asset amort expens non-cash charg conting
consider adjust specifi item
abbvi adjust earn per share repres growth
compar adjust earn per share increas
total revenu
sever key product contribut growth
global oper sale growth nearli hematolog
oncolog busi imbruvica perform except well robust
share growth across multipl line therapi cll includ new patient share
frontlin set share point past year
intern humira sale oper basi reflect
impact direct biosimilar competit europ intern
market intern biosimilar trend dynam remain consist
expect
announc definit transact agreement acquir allergan
significantli expand diversifi revenu base new
therapeut area enhanc long-term fund capac allow
continu invest innov scienc
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin increas ttm basi compar
oper margin increas ttm basi compar
net margin ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag marginsprofitabilityrevenu growth oper incom growthep growth abbvi inc octob
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale abbvi inc octob
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn asset inc octob
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net net margin annual itemsquarterli item abbvi inc octob
balanc sheet ratio
outstand equival market debt common purchas properti plant purchas purchas sale repurchas net issuanc net chang capit free abbvi inc octob
current price-to-earnings lower price-to-earnings surg
januari price-to-earnings fallen sinc due fall stock price result failur
drug rova acquir averag price-to-earnings expect forward price-to-earnings
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit research global fmr geod capit manag northern trust orbi gray top mutual fund holdersholdersharesd report outvaluevanguard total stock market invest compani capit incom builder vanguard capit world growth incom spdr etf vanguard institut fund-institut american mutual fund fidel fund amcap competit
developmentsabbvi announc new data dermatolog portfolio pipelin european academi dermatolog venereolog eadv congress octob announc present new result evalu safeti efficaci skyrizi year adult patient moder sever plaqu psoriasi well addit data humira investig jak inhibitor upadacitinib european academi dermatolog venereolog eadv congress octob madrid abbvi receiv fda approv mavyret shorten treatment durat eight week treatment-nav patient chronic hepat compens cirrhosi across genotyp septemb today announc food drug administr grant approv mavyret shorten once-daili treatment durat week treatment-nav compens cirrhot chronic hepat patient across genotyp august mavyret receiv regulatori approv week pan-genotyp treatment treatment naiv hcv patient without cirrhosi abbvi discontinu rovalpituzumab tesirin rova-t research develop programaugust today announc meru phase trial evalu rova-t first-lin mainten therapi advanc small-cel lung cancer sclc demonstr surviv benefit pre-plan interim analysi patient receiv rova-t compar placebo overal safeti profil gener consist observ previou studi meru trial close rova-t research develop program termin abbvi move forward priorit develop program within oncolog pipelin abbvi receiv fda approv rinvoq oral jak inhibitor treatment moder sever rheumatoid arthritisaugust today announc food drug administr approv rinvoq daili oral janu kinas inhibitor treartment adult moder sever activ rheumatoid arthriti ra inadequ respons intoler methotrex rinvoq expect avail late august abbvi inc octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
perform
compar
roa roi
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit consensu view analyst trend stock
forecast
lower
compar
forward price-to-earnings
lower
compar
abbv avgfive-year growth forecast usdgrowth high day day day estim comparisonabbvindustri avg avgprice/earn yield consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last daysobsoleteobsoleteobsoleteobsoletedown last dayscurr surprisescurr growth rate analyst recommend
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price dip august went upward trend
stock gave return quarter current trade
stock price show declin trend past declin
rang stock
stock price show upward trend till februari surg later show
stock given return past
abbvi revenu quarter increas cc basi due increas global
revenu hematolog oncolog product maintain rate buy upsid potenti
increas due decreas stock price period howev maintain
expect growth revenu growth revenu
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
